14790-42-2

Usage

Uses

Used in Pharmaceutical Industry:
4-chloro-2-phenylpyrimidine is used as a chemical intermediate for the synthesis of pharmaceuticals, particularly for the development of antiviral and anticancer drugs. Its unique structure allows for the creation of novel therapeutic agents that can target specific biological pathways.
Used in Agrochemical Industry:
4-chloro-2-phenylpyrimidine is also utilized as a precursor in the synthesis of agrochemicals, contributing to the development of new pesticides and other agricultural products that can improve crop protection and yield.
Used in Dye Production:
4-chloro-2-phenylpyrimidine is used as a key component in the production of dyes, where its chemical properties enable the creation of a wide range of colors and hues for various applications, including textiles, plastics, and printing inks.
Used in Organic Compound Synthesis:
Due to its reactive nature, 4-chloro-2-phenylpyrimidine serves as a valuable building block in the synthesis of other organic compounds, expanding the scope of chemical research and development in various industries.
It is crucial to handle 4-chloro-2-phenylpyrimidine with care, considering its potentially hazardous properties, to ensure the safety of both individuals and the environment.

InChI:InChI=1/C10H7ClN2/c11-9-6-7-12-10(13-9)8-4-2-1-3-5-8/h1-7H

Upstream product

• 33630-20-5 2-phenyl-4-methoxypyrimidine 
• 33630-25-0 4-amino-2-phenylpyrimidine 
• 33643-94-6 2-phenyl-4-hydroxypyrimidine 
• 618-39-3 benzamidin 
• 33643-94-6 4-oxo-2-phenyl-3,4-dihydropyrimidine 
• 98-80-6 phenylboronic acid 
• 10026-13-8 phosphorus pentachloride 

Downstream Products

• 7431-45-0 2-phenylpyrimidine 
• 33630-25-0 4-amino-2-phenylpyrimidine 
• 35594-07-1 (2-phenyl-pyrimidin-4-yl)-hydrazine 
• 88236-12-8 4-azido-2-phenylpyrimidine 
• 88236-29-7 [3-(2-Phenyl-pyrimidin-4-yl)-3H-[1,2,3]triazol-4-yl]-methanol 
• 88236-27-5 2-Phenyl-4-(5-phenyl-[1,2,3]triazol-1-yl)-pyrimidine 
• 88236-21-9 2-Phenyl-4-(4-phenyl-[1,2,3]triazol-1-yl)-pyrimidine 
• 88236-18-4 1-(2-Phenyl-pyrimidin-4-yl)-1H-[1,2,3]triazole-4,5-dicarboxylic acid dimethyl ester 
• 126382-57-8 Phenyl-(2-phenyl-pyrimidin-4-yl)-diazene 
• 126382-51-2 4-Nitroso-2-phenyl-pyrimidine 
• 69491-52-7 2-(3-nitrophenyl)pyrimidine 
• 823796-44-7 C₂HF₃O₂*C₁₂H₁₃N₃ 
• 1163123-05-4 (5-methyl-2-trifluoromethyl-phenyl)-[(R)-3-(2-phenyl-pyrimidin-4-ylamino)-pyrrolidin-1-yl]-methanone 
• 1293938-49-4 8-[(2,5-dimethylphenyl)sulfonyl]-3-(2-phenylpyrimidin-4-yl)-3,8-diazabicyclo[4.2.0]octane 

Relevant academic research and scientific papers

Deaminative chlorination of aminoheterocycles

Selective modification of heteroatom-containing aromatic structures is in high demand as it permits rapid evaluation of molecular complexity in advanced intermediates. Inspired by the selectivity of deaminases in nature, herein we present a simple methodology that enables the NH2 groups in aminoheterocycles to be conceived as masked modification handles. With the aid of a simple pyrylium reagent and a cheap chloride source, C(sp2)?NH2 can be converted into C(sp2)?Cl bonds. The method is characterized by its wide functional group tolerance and substrate scope, allowing the modification of >20 different classes of heteroaromatic motifs (five- and six-membered heterocycles), bearing numerous sensitive motifs. The facile conversion of NH2 into Cl in a late-stage fashion enables practitioners to apply Sandmeyer- and Vilsmeier-type transforms without the burden of explosive and unsafe diazonium salts, stoichiometric transition metals or highly oxidizing and unselective chlorinating agents. [Figure not available: see fulltext.]

Discovery of wtRET and V804MRET Inhibitors: From Hit to Lead

Oncogenic activation of RET kinase has been found in several neoplastic diseases, like medullary thyroid carcinoma, multiple endocrine neoplasia, papillary thyroid carcinoma, and non-small-cell lung cancer. Currently approved RET inhibitors were not originally designed to be RET inhibitors, and their potency against RET kinase has not been optimized. Hence, novel compounds able to inhibit both wild-type RET (wtRET) and its mutants (e.g., V804MRET) are needed. Herein we present the development and the preliminary evaluation of a new sub-micromolar wtRET/V804MRET inhibitor, N-(2-fluoro-5-trifluoromethylphenyl)-N′-{4′-[(2′′-benzamido)pyridin-4′′-ylamino]phenyl}urea (69), endowed with a 4-anilinopyridine structure, starting from our previously identified 4-anilinopyrimidine hit compound. Profiling against a panel of kinases indicated 69 as a multi cKIT/wtRET/V804MRET inhibitor.

Microwave-assisted, efficient and regioselective Pd-catalyzed C-phenylation of halopyrimidines

We herein report that flash heating microwave irradiation is a helpful tool in the formation of arylpyrimidines from the corresponding halopyrimidines. The palladium-catalyzed cross-coupling reactions of 2,4-di- and 2,4,5-trihalopyrimidines with phenylboronic acid under the above conditions are described. By use of the appropriate catalyst and the adequate halopyrimidine, good regioselectivity can be achieved in the 2-, 4-, or 5-positions of the heterocycle. In addition, we show that this methodology is ameneable for the stepwise preparation of mono-, di-, and triphenylpyrimidines.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AND METHODS OF USE

The present invention relates to pyridines, pyrimidines and derivatives thereof, and pharmaceutically acceptable salts thereof. Also included is a method of treatment of inflammation, rheumatoid arthritis, Pagets disease, osteoporosis, multiple myeloma, uveititis, acute or chronic myelogenous leukemia, pancreatic beta cell destruction, osteoarthritis, rheumatoid spondylitis, gouty arthritis, inflammatory bowel disease, adult respiratory distress syndrome (ARDS), psoriasis, Crohn's disease, allergic rhinitis, ulcerative colitis, anaphylaxis, contact dermatitis, asthma, muscle degeneration, cachexia, Reiter's syndrome, type I diabetes, type II diabetes, bone resorption diseases, graft vs. host reaction, Alzheimer's disease, stroke, myocardial infarction, ischemia reperfusion injury, atherosclerosis, brain trauma, multiple sclerosis, cerebral malaria, sepsis, septic shock, toxic shock syndrome, fever, myalgias due to HIV-1, HIV-2, HIV-3, cytomegalovirus (CMV), influenza, adenovirus, the herpes viruses or herpes zoster infection in a mammal comprising administering an effective amount a compound as described above.

PYRIMIDINES USEFUL AS MODULATORS OF VOLTAGE-GATED ION CHANNELS

The present invention relates to compounds useful as inhibitors of voltage-gated ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.